IMGN632: A Novel Antibody Drug Conjugate (ADC) of a CD123-Targeting Antibody with a Potent DNA-Alkylator is Highly Active in Preclinical Models of AML with Poor Prognosis
IMMUNOGEN IS NOW PART OF ABBVIE
Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.